Basic Mechanisms of Itch and Advances in Clinical Management.

IF 4.7 2区 医学 Q1 ALLERGY
Giulia Coscarella, Elise Edwards, Gil Yosipovitch
{"title":"Basic Mechanisms of Itch and Advances in Clinical Management.","authors":"Giulia Coscarella, Elise Edwards, Gil Yosipovitch","doi":"10.1016/j.anai.2025.09.014","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic pruritus requires comprehensive assessment and management due to its profound impact on quality of life. The etiologies of pruritus are diverse, encompassing dermatologic, neuropathic, systemic, psychogenic, and mixed causes. Pruritogens activate C and Aδ fibers through histaminergic and non-histaminergic pathways. Increasing evidence highlights the role of Th2 cytokines, particularly interleukin (IL)-4, IL-13, and IL-31, which directly stimulate sensory neurons and perpetuate the itch-scratch cycle. Itch perception arises from dynamic interactions between the immune system and the peripheral and central nervous systems. Signals transmitted by sensory fibers are processed in the dorsal horn and relayed to thalamic and cortical centers, reinforcing chronicity. Diagnostic evaluation begins with detailed history and examination, complemented by laboratory testing such as complete blood count, kidney, liver, glucose, and thyroid function tests to uncover systemic or neurologic contributors. For dermatologic conditions, topical immunomodulators-including corticosteroids, calcineurin inhibitors, and PDE4 inhibitors- are first-line options for localized itch. Extensive itch may require systemic immunosuppressants or phototherapy. Biologic agents targeting IL-4/IL-13 and IL-31 pathways have revolutionized treatment for atopic dermatitis and prurigo nodularis, while JAK-STAT inhibitors also offer significant antipruritic effect in atopic dermatitis and beyond. Neuropathic itch may respond to topical anesthetics: menthol, pramoxine, capsaicin, or compounded ketamine-amitriptyline-lidocaine formulations, as well as systemic gabapentinoids and antidepressants. Systemic or intractable pruritus may benefit from kappa opioid receptor agonists. New drugs targeting the mast cell such as BTK inhibitors, c-KIT inhibitors, and MRGPRX2 antagonists have robust anti-pruritic effects in mast cell-mediated diseases. Supportive measures, including psychosocial interventions, remain integral to long-term management.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Allergy Asthma & Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.anai.2025.09.014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic pruritus requires comprehensive assessment and management due to its profound impact on quality of life. The etiologies of pruritus are diverse, encompassing dermatologic, neuropathic, systemic, psychogenic, and mixed causes. Pruritogens activate C and Aδ fibers through histaminergic and non-histaminergic pathways. Increasing evidence highlights the role of Th2 cytokines, particularly interleukin (IL)-4, IL-13, and IL-31, which directly stimulate sensory neurons and perpetuate the itch-scratch cycle. Itch perception arises from dynamic interactions between the immune system and the peripheral and central nervous systems. Signals transmitted by sensory fibers are processed in the dorsal horn and relayed to thalamic and cortical centers, reinforcing chronicity. Diagnostic evaluation begins with detailed history and examination, complemented by laboratory testing such as complete blood count, kidney, liver, glucose, and thyroid function tests to uncover systemic or neurologic contributors. For dermatologic conditions, topical immunomodulators-including corticosteroids, calcineurin inhibitors, and PDE4 inhibitors- are first-line options for localized itch. Extensive itch may require systemic immunosuppressants or phototherapy. Biologic agents targeting IL-4/IL-13 and IL-31 pathways have revolutionized treatment for atopic dermatitis and prurigo nodularis, while JAK-STAT inhibitors also offer significant antipruritic effect in atopic dermatitis and beyond. Neuropathic itch may respond to topical anesthetics: menthol, pramoxine, capsaicin, or compounded ketamine-amitriptyline-lidocaine formulations, as well as systemic gabapentinoids and antidepressants. Systemic or intractable pruritus may benefit from kappa opioid receptor agonists. New drugs targeting the mast cell such as BTK inhibitors, c-KIT inhibitors, and MRGPRX2 antagonists have robust anti-pruritic effects in mast cell-mediated diseases. Supportive measures, including psychosocial interventions, remain integral to long-term management.

瘙痒的基本机制及临床治疗进展。
由于慢性瘙痒对生活质量的深刻影响,需要全面的评估和管理。瘙痒的病因是多种多样的,包括皮肤病、神经性、全身性、心因性和混合病因。搔痒原通过组胺能和非组胺能途径激活C和Aδ纤维。越来越多的证据强调了Th2细胞因子的作用,特别是白细胞介素(IL)-4、IL-13和IL-31,它们直接刺激感觉神经元并使瘙痒-抓痒循环持续下去。瘙痒感产生于免疫系统与外周和中枢神经系统之间的动态相互作用。由感觉纤维传递的信号在背角被处理并传递到丘脑和皮层中心,从而加强了慢性。诊断评估从详细的病史和检查开始,辅以实验室检查,如全血细胞计数、肾、肝、葡萄糖和甲状腺功能检查,以发现全身性或神经系统疾病。对于皮肤病,局部免疫调节剂——包括皮质类固醇、钙调磷酸酶抑制剂和PDE4抑制剂——是局部瘙痒的一线选择。广泛的瘙痒可能需要全身免疫抑制剂或光疗。靶向IL-4/IL-13和IL-31途径的生物制剂已经彻底改变了特应性皮炎和结节性痒疹的治疗,而JAK-STAT抑制剂也在特应性皮炎及其他疾病中具有显著的止痒作用。神经性瘙痒可能对局部麻醉剂有反应:薄荷醇、普拉莫辛、辣椒素或复合氯胺酮-阿米替林-利多卡因制剂,以及全身加巴喷丁类药物和抗抑郁药。系统性或难治性瘙痒可能受益于阿片受体激动剂。针对肥大细胞的新药物,如BTK抑制剂、c-KIT抑制剂和MRGPRX2拮抗剂,在肥大细胞介导的疾病中具有强大的抗瘙痒作用。支持性措施,包括社会心理干预,仍然是长期管理的组成部分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.50
自引率
6.80%
发文量
437
审稿时长
33 days
期刊介绍: Annals of Allergy, Asthma & Immunology is a scholarly medical journal published monthly by the American College of Allergy, Asthma & Immunology. The purpose of Annals is to serve as an objective evidence-based forum for the allergy/immunology specialist to keep up to date on current clinical science (both research and practice-based) in the fields of allergy, asthma, and immunology. The emphasis of the journal will be to provide clinical and research information that is readily applicable to both the clinician and the researcher. Each issue of the Annals shall also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信